In the BioHarmony Drug Report Database
Lemborexant
Dayvigo (lemborexant) is a small molecule pharmaceutical. Lemborexant was first approved as Dayvigo on 2020-04-07. It is used to treat sleep initiation and maintenance disorders in the USA. The pharmaceutical is active against orexin receptor type 2 and orexin receptor type 1. Dayvigo’s patent is valid until 2035-10-21 (FDA).
Trade Name
|
Dayvigo |
|---|---|
Common Name
|
lemborexant |
ChEMBL ID
|
CHEMBL3545367 |
Indication
|
sleep initiation and maintenance disorders |
Drug Class
|
Orexin antagonist |
Image (chem structure or protein)